FOLR1
Folate receptor alpha
As of the edition of 20 October 2026, FOLR1 (folate receptor alpha, UniProt P15328) has 10 drugs tested at it and 12 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15328
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Lungs and airways; Digestive system; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 77
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 3 |
| Stopped | 4 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mirvetuximab soravtansine | Marketed | Phase 3 | Ends 2034 |
| Pafolacianine | Marketed | Phase 4 | Ends 2035 |
| Vintafolide | Stopped | Phase 3 | none listed |
| Farletuzumab | Stopped | Phase 2 | none listed |
| Luveltamab tazevibulin | Stopped | Phase 3 | none listed |
| Farletuzumab ecteribulin | Active | Phase 2 | none listed |
| AZD5335 | Active | Phase 3 | none listed |
| Pasifolate exatecan | Stopped | Phase 2 | none listed |
| ZW191 | Active | Phase 1 | none listed |
| Mirvetuximab | Marketed | No phase stated | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Engaged | 5 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| On Target | Route B |
| Novartis | Route A |
| Sutro Biopharma | Route A |
The other 9 companies at FOLR1
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at FOLR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.